. Author manuscript; available in PMC: 2017 Jul 1.

Published in final edited form as: J Clin Virol. 2016 May 10;80:93–97. doi: 10.1016/j.jcv.2016.05.003

Table 2.

Reduction in HCV prevalence but not HSV-2 prevalence among HIV positive individuals.

Study Year	HCV Co-infection		HSV-2 Coinfection
	N (% Pos.)	aPR (95% CI)	N (% Pos.)	aPR (95% CI)
	2003	228 (59.6)	(ref)	228 (79.8)	(ref)
2007	265 (53.6)	0.89 (0.77–1.04)	265 (79.6)	1.02 (0.94–1.11)
2013	262 (48.1)	0.79 (0.67–0.93)	258 (78.3)	1.01 (0.92–1.10)

Adjusted prevalence ratios (aPR) were calculated from a multivariate model that included HCV/HSV-2 co-infection, age group, gender, and race. Prevalence in 2003 was the reference group, and aPRs with a P<0.05 are shown in bold. N represents the number of individuals analyzed.